Helenalin

6754-13-8

262.30

10 mM in DMSO

NF-kappaB

Helenalin is an anti-inflammatory sesquiterpene lactone. Helenalin selectively inhibits transcription factor NF-kappaB by directly targeting p65. Helenalin has alkylating activity, targets the cysteine sulfhydryl groups in the p65 subunit of NF-kappaB, thereby inhibits its DNA binding^[1][2]. In Vitro: Helenalin (10 uM; 20-120 minutes) causes complete inhibition of NF-kappaB DNA binding after 80 minutes^[1].
The anti-inflammatory, anti-carcinogenic phytochemical, Helenalin is a potent inhibitor of periodic Skp2 accumulation, an F-box protein mediating SCF E3 ligase ubiquitylation and degradation of both CKIs during S phase progression^[3]. In Vivo: Helenalin (25 mg/kg; i.p.; 6 to 12 hours) administers to immature male ICR mice caused a rapid decrease in hepatic glutathione levels^[2].